药品注册申请号:050590
申请类型:NDA (新药申请)
申请人:GLAXOSMITHKLINE
申请人全名:GLAXOSMITHKLINE
产品信息
产品号商品名活性成分剂型/给药途径规格/剂量参比药物(RLD)生物等效参考标准(RS)治疗等效代码该申请号批准日期该产品号批准日期市场状态
001 TIMENTIN CLAVULANATE POTASSIUM; TICARCILLIN DISODIUM INJECTABLE;INJECTION EQ 100MG BASE/VIAL;EQ 3GM BASE/VIAL No No None 1985/04/01 1985/04/01 Discontinued
002 TIMENTIN CLAVULANATE POTASSIUM; TICARCILLIN DISODIUM INJECTABLE;INJECTION EQ 200MG BASE/VIAL;EQ 3GM BASE/VIAL No No None 1985/04/01 Discontinued
003 TIMENTIN CLAVULANATE POTASSIUM; TICARCILLIN DISODIUM INJECTABLE;INJECTION EQ 1GM BASE/VIAL;EQ 30GM BASE/VIAL No No None 1987/08/18 Discontinued
批准日期,申请提交历史,通知信,药品说明书,审评文件等信息
提交状态日期提交号审批结论申请内容分类审评优先级;罕用药状态通知信、审评文件、说明书、包装标签备注
2014/06/12 SUPPL-69(补充) Approval Labeling STANDARD
2014/02/12 SUPPL-68(补充) Approval Manufacturing (CMC) PRIORITY
2013/09/27 SUPPL-67(补充) Approval Labeling STANDARD
2013/07/19 SUPPL-66(补充) Approval Manufacturing (CMC) PRIORITY
2013/03/20 SUPPL-65(补充) Approval Manufacturing (CMC) PRIORITY
2012/10/04 SUPPL-62(补充) Approval Labeling STANDARD
2011/06/09 SUPPL-61(补充) Approval Labeling STANDARD
2011/06/09 SUPPL-60(补充) Approval Labeling STANDARD
2010/12/20 SUPPL-59(补充) Approval Labeling STANDARD
2010/12/20 SUPPL-58(补充) Approval Labeling STANDARD
2008/05/08 SUPPL-55(补充) Approval Labeling STANDARD
2008/04/17 SUPPL-57(补充) Approval Labeling STANDARD
2007/03/15 SUPPL-54(补充) Approval Labeling STANDARD
2004/11/19 SUPPL-52(补充) Approval Labeling STANDARD
2003/01/03 SUPPL-48(补充) Approval Manufacturing (CMC) PRIORITY
2002/10/17 SUPPL-47(补充) Approval Manufacturing (CMC) PRIORITY
2002/05/17 SUPPL-27(补充) Approval Labeling STANDARD
2002/03/18 SUPPL-40(补充) Approval Labeling STANDARD
2002/02/08 SUPPL-44(补充) Approval Manufacturing (CMC) PRIORITY
2001/08/16 SUPPL-43(补充) Approval Manufacturing (CMC) PRIORITY
2001/08/02 SUPPL-42(补充) Approval Manufacturing (CMC) PRIORITY
2001/08/02 SUPPL-41(补充) Approval Manufacturing (CMC) PRIORITY
1999/11/19 SUPPL-37(补充) Approval Manufacturing (CMC) PRIORITY
1999/09/23 SUPPL-36(补充) Approval Manufacturing (CMC) PRIORITY
1999/07/07 SUPPL-32(补充) Approval Manufacturing (CMC) PRIORITY
1999/02/01 SUPPL-35(补充) Approval Manufacturing (CMC) PRIORITY
1998/02/05 SUPPL-34(补充) Approval Manufacturing (CMC) PRIORITY
1997/12/11 SUPPL-30(补充) Approval Efficacy STANDARD
1997/08/29 SUPPL-33(补充) Approval Manufacturing (CMC) PRIORITY
1997/06/17 SUPPL-31(补充) Approval Manufacturing (CMC) PRIORITY
1996/02/27 SUPPL-29(补充) Approval Labeling STANDARD
1996/01/19 SUPPL-25(补充) Approval Labeling STANDARD
1995/04/18 SUPPL-28(补充) Approval Manufacturing (CMC) PRIORITY
1994/09/16 SUPPL-26(补充) Approval Manufacturing (CMC) PRIORITY
1993/06/08 SUPPL-24(补充) Approval Manufacturing (CMC) PRIORITY
1993/06/08 SUPPL-23(补充) Approval Manufacturing (CMC) PRIORITY
1993/01/07 SUPPL-22(补充) Approval Labeling STANDARD
1992/03/26 SUPPL-20(补充) Approval Labeling
1992/03/26 SUPPL-19(补充) Approval Labeling
1992/01/02 SUPPL-18(补充) Approval Manufacturing (CMC) PRIORITY
1991/12/17 SUPPL-16(补充) Approval Efficacy
1990/02/26 SUPPL-17(补充) Approval Manufacturing (CMC) PRIORITY
1989/04/20 SUPPL-15(补充) Approval Manufacturing (CMC) PRIORITY
1989/04/20 SUPPL-14(补充) Approval Manufacturing (CMC) PRIORITY
1988/08/24 SUPPL-13(补充) Approval Manufacturing (CMC) PRIORITY
1988/05/16 SUPPL-12(补充) Approval Labeling
1987/12/01 SUPPL-21(补充) Approval Labeling
1987/10/23 SUPPL-10(补充) Approval Efficacy
1987/08/18 SUPPL-11(补充) Approval Labeling
1986/02/14 SUPPL-9(补充) Approval Manufacturing (CMC) PRIORITY
1985/11/26 SUPPL-6(补充) Approval Manufacturing (CMC) PRIORITY
1985/11/26 SUPPL-5(补充) Approval Manufacturing (CMC) PRIORITY
1985/08/12 SUPPL-4(补充) Approval Manufacturing (CMC) PRIORITY
1985/05/13 SUPPL-1(补充) Approval Manufacturing (CMC) PRIORITY
1985/04/19 SUPPL-2(补充) Approval Manufacturing (CMC) PRIORITY
1985/04/18 SUPPL-3(补充) Approval Labeling
1985/04/01 ORIG-1(原始申请) Approval Type 4 - New Combination PRIORITY
与本品相关的专利信息(来自FDA橙皮书Orange Book)
关联产品号专利号专利过期日是否物质专利是否产品专利专利用途代码撤销请求提交日期专利下载备注
与本品相关的市场独占权保护信息
关联产品号独占权代码失效日期备注
与本品治疗等效的药品
本品无治疗等效药品
更多信息
药品NDC数据与药品包装、标签说明书
©2006-2024 DrugFuture->U.S. FDA Drugs Database